Bruker (NASDAQ:BRKR) Stock Keeps Neutral Rating at JPMorgan Chase & Co.

Key Points

• JPMorgan reaffirmed its “neutral” rating on Bruker and maintained a $60 price target, implying approximately 6.78% upside from the stock’s $56.19 opening price.
• Analyst sentiment remains broadly positive, with Bruker holding a consensus “Moderate Buy” rating and an average price target of $59.43, despite ratings ranging from sell to strong buy.
• Bruker exceeded quarterly EPS expectations, reporting $0.49 versus the $0.38 consensus estimate, while revenue rose 5.2% year over year but fell short of forecasts. Institutional investors own 79.52% of the company, and an insider recently sold 2,000 shares.

Bruker (NASDAQ:BRKR - Get Free Report)'s stock had its "neutral" rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $60.00 target price on the medical research company's stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 6.78% from the stock's current price.

Several other research firms have also recently weighed in on BRKR. Weiss Ratings reiterated a "sell (d+)" rating on shares of Bruker in a report on Monday, August 31st. TD Cowen boosted their price objective on Bruker from $60.00 to $62.00 and gave the company a "hold" rating in a research report on Tuesday. Leerink Partners increased their target price on Bruker from $60.00 to $80.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 29th. Guggenheim increased their target price on Bruker from $70.00 to $72.00 and gave the stock a "buy" rating in a research note on Thursday, October 1st. Finally, Zacks Research downgraded shares of Bruker from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $59.43.

Bruker Stock Down 0.1%

Shares of BRKR opened at $56.19 on Wednesday. The business's fifty day moving average price is $58.59 and its two-hundred day moving average price is $53.04. The firm has a market capitalization of $8.56 billion, a price-to-earnings ratio of -80.27, a PEG ratio of 1.72 and a beta of 1.22. Bruker has a 52 week low of $32.37 and a 52 week high of $66.98. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. Bruker's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts predict that Bruker will post 2.12 earnings per share for the current year.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the company's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares in the company, valued at $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 27.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bruker

Hedge funds and other institutional investors have recently modified their holdings of the company. Pallas Capital Advisors LLC bought a new position in Bruker in the 2nd quarter valued at about $570,746,000. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Bruker in the 2nd quarter valued at approximately $169,899,000. Sculptor Capital LP raised its position in shares of Bruker by 9.0% in the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock valued at $118,112,000 after buying an additional 270,000 shares in the last quarter. Alyeska Investment Group L.P. lifted its holdings in shares of Bruker by 86.2% during the 2nd quarter. Alyeska Investment Group L.P. now owns 1,410,164 shares of the medical research company's stock worth $84,864,000 after acquiring an additional 653,007 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Bruker by 23.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company's stock worth $84,556,000 after acquiring an additional 448,440 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company's portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.